Brian Culley
Chief Executive Officer chez LINEAGE CELL THERAPEUTICS, INC.
Fortune : 214 366 $ au 31/03/2024
Profil
Brian M.
Culley is currently the President, Chief Executive Officer, CAO & Director at Lineage Cell Therapeutics, Inc. since 2022.
He is also the Chief Executive & Financial Officer at Asterias Biotherapeutics, Inc. since 2019.
Previously, he served as the Chief Executive Officer & Director at Mast Therapeutics, Inc. from 2011 to 2017.
He was also the Chief Executive Officer at Manuka, Inc. from 2017 to 2018.
Additionally, he held the position of Chief Executive Officer & Director at Savara, Inc. He worked as the Director-Business Development & Marketing at iTherX Pharmaceuticals, Inc. from 2002 to 2004.
He was a Director at Orphagen Pharmaceuticals from 2017 to 2022.
Prior to that, he worked as a Licensing & Marketing Associate at the University of California, Berkeley from 1999 to 2000.
Mr. Culley completed his undergraduate degree at Boston College and his graduate degree at the University of California, Santa Barbara.
He also holds an MBA from the Johnson Graduate School of Management.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 07/03/2024 | 144 842 ( 0,08% ) | 214 366 $ | 31/03/2024 |
Postes actifs de Brian Culley
| Sociétés | Poste | Début |
|---|---|---|
| LINEAGE CELL THERAPEUTICS, INC. | Chief Executive Officer | 17/09/2018 |
| ASTERIAS BIOTHERAPEUTICS INC | Chief Executive Officer | 08/03/2019 |
Anciens postes connus de Brian Culley
| Sociétés | Poste | Fin |
|---|---|---|
Orphagen Pharmaceuticals
 Orphagen Pharmaceuticals Pharmaceuticals: MajorHealth Technology Orphagen Pharmaceuticals develops and manufactures drugs. The company was founded by Scott Thacher in 2001 and is headquartered in San Diego, CA. | Director/Board Member | 01/12/2022 |
| MANUKA, INC. | Chief Executive Officer | 17/09/2018 |
Mast Therapeutics, Inc.
 Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | Chief Executive Officer | 28/04/2017 |
| SAVARA INC. | Chief Executive Officer | 27/04/2017 |
iTherX Pharmaceuticals, Inc.
 iTherX Pharmaceuticals, Inc. Medical DistributorsDistribution Services iTherX is a clinical stage pharmaceutical company focused on the discovery and development of innovative treatments for Hepatitis C. This is a disease that affects almost 3% of the world's population, and is the major cause of chronic liver disease, cirrhosis, liver failure and primary liver cancer. Currently there is only a single mode of therapy and less than 5% of patients can be successfully treated. The company continues to carry out focused research in their areas of expertise to provide sustainability of product pipelines. In an era of managed care and increased regulatory scrutiny, it is easy to yield to the temptation of producing 'me too drugs'. However, they think that innovation in the development of pharmaceutical products is important because it is the only way to improve the outcomes for patients. As such, they also think that innovation can ensure the financial returns that investors in health care deserve for the risks that they take. Their innovative approach is evident in their pipeline of Hepatitis C drug candidates. As new and better treatments are being sought, most companies involved in this effort are targeting the enzymes responsible for viral replication: polymerases and proteases. While these are important targets, there is a great deal of duplication of effort in these initiatives. At iTherX, they are pioneering the development of a novel class of HCV antivirals by targeting the steps involved in the entry of the hepatitis C virus into liver cells. Their Host Cell Receptor Target Program engenders small molecule compounds that target a liver cell membrane protein, SR-B1, which recognize and dock the virus. Their lead compound, ITX5061, has extensive safety data in over 250 patients, and shows picomolar potency in inhibiting HCV infection in vitro. They plan to initiate a Phase 2a clinical trial in HCV patients in Q2 of 2009. They have also used medicinal chemistry to develop back-up compounds for this program, and a clinical candidate has been selected for development. Another innovative program is novel cell receptor, which develops antagonists (including biologics) against a novel liver cell membrane protein required for infectivity of the virus. | Sales & Marketing | 01/01/2004 |
Formation de Brian Culley
| Boston College | Undergraduate Degree |
| University of California, Santa Barbara | Graduate Degree |
| Johnson Graduate School of Management | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| LINEAGE CELL THERAPEUTICS, INC. | Health Technology |
| MANUKA, INC. | Health Technology |
| SAVARA INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
iTherX Pharmaceuticals, Inc.
iTherX Pharmaceuticals, Inc. Medical DistributorsDistribution Services iTherX is a clinical stage pharmaceutical company focused on the discovery and development of innovative treatments for Hepatitis C. This is a disease that affects almost 3% of the world's population, and is the major cause of chronic liver disease, cirrhosis, liver failure and primary liver cancer. Currently there is only a single mode of therapy and less than 5% of patients can be successfully treated. The company continues to carry out focused research in their areas of expertise to provide sustainability of product pipelines. In an era of managed care and increased regulatory scrutiny, it is easy to yield to the temptation of producing 'me too drugs'. However, they think that innovation in the development of pharmaceutical products is important because it is the only way to improve the outcomes for patients. As such, they also think that innovation can ensure the financial returns that investors in health care deserve for the risks that they take. Their innovative approach is evident in their pipeline of Hepatitis C drug candidates. As new and better treatments are being sought, most companies involved in this effort are targeting the enzymes responsible for viral replication: polymerases and proteases. While these are important targets, there is a great deal of duplication of effort in these initiatives. At iTherX, they are pioneering the development of a novel class of HCV antivirals by targeting the steps involved in the entry of the hepatitis C virus into liver cells. Their Host Cell Receptor Target Program engenders small molecule compounds that target a liver cell membrane protein, SR-B1, which recognize and dock the virus. Their lead compound, ITX5061, has extensive safety data in over 250 patients, and shows picomolar potency in inhibiting HCV infection in vitro. They plan to initiate a Phase 2a clinical trial in HCV patients in Q2 of 2009. They have also used medicinal chemistry to develop back-up compounds for this program, and a clinical candidate has been selected for development. Another innovative program is novel cell receptor, which develops antagonists (including biologics) against a novel liver cell membrane protein required for infectivity of the virus. | Distribution Services |
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | Health Technology |
Asterias Biotherapeutics, Inc.
 Asterias Biotherapeutics, Inc. BiotechnologyHealth Technology Asterias Biotherapeutics, Inc. is a clinical-stage biotechnology company, which focuses on developing and commercializing novel therapies in the emerging fields of cell therapy and regenerative medicine. Its product candidates include AST-OPC1, trial for spinal cord injuries; AST-VAC1, a patient specific cancer immunotherapy focused on acute myeloid leukemia; and AST-VAC2, a non-patient-specific cancer immunotherapy for non-small cell lung cancer. The company was founded on September 24, 2012 and is headquartered in Fremont, CA. | Health Technology |
Orphagen Pharmaceuticals
Orphagen Pharmaceuticals Pharmaceuticals: MajorHealth Technology Orphagen Pharmaceuticals develops and manufactures drugs. The company was founded by Scott Thacher in 2001 and is headquartered in San Diego, CA. | Health Technology |
